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on Coronary Microvascular Function After a
Recent Myocardial Infarction
Brian B. Løgstrup, MD,* Dan E. Høfsten, MD, PHD,* Thomas B. Christophersen, MD,*
Jacob E. Møller, MD, DMSC,† Hans E. Bøtker, MD, DMSC,‡ Patricia A. Pellikka, MD,§
Kenneth Egstrup, MD, DMSC*
Svendborg, Copenhagen, and Aarhus, Denmark; and Rochester, Minnesota
O B J E C T I V E S This study sought to assess the association between abnormal glucose metabolism
and abnormal coronary ﬂow reserve (CFR) in patients with a recent acute myocardial infarction (AMI).
B A C KG ROUND Mortality and morbidity after AMI is high among patients with abnormal glucose
metabolism, which may be related to abnormal microcirculation.
METHOD S We studied 183 patients with a ﬁrst AMI. In 161 patients with no history of diabetes
mellitus (DM), an oral glucose tolerance test was performed, and patients were categorized according
to World Health Organization criteria for whole blood glucose into 3 groups. After coronary angiography
and revascularization, a comprehensive transthoracic echocardiogram and noninvasive assessment of
CFR was performed in the distal part of left descending artery, as an indicator of microvascular function.
Adenosine was administered by intravenous infusion (140 g/kg/min) to obtain the hyperemic ﬂow
proﬁles. The CFR was deﬁned as the ratio of hyperemic to baseline peak diastolic coronary ﬂow
velocities.
R E S U L T S Median CFR was 1.9 (interquartile range [IQR] 1.4 to 2.4], and 109 (60%) patients had a CFR
2. The lowest CFR was seen in patients with a history of DM (1.4 [IQR 1.4 to 1.7], n 22) and in patients
with newly diagnosed DM (1.6 [IQR 1.3 to 2], n  39), whereas CFR did not differ in patients with
abnormal glucose tolerance (2.1 [IQR 1.4 to 2.6], n  58) and in patients with normal glucose tolerance
(2.2 [IQR 1.7 to 2.6], n  62). In a stepwise logistic regression model adjusting for age, sex, site and size
of AMI, heart rate, risk factors of the metabolic syndrome, degree of angiographic evidence of coronary
artery disease, and medical therapy, newly diagnosed DM (odds ratio: 3.0) and a history of DM (odds
ratio: 9.9) remained signiﬁcant predictors of CFR 2, whereas impaired glucose tolerance was not.
CONC L U S I O N S CFR is decreased in patients with known or newly diagnosed DM even after
adjustment of possible confounders, whereas CFR in patients with impaired glucose tolerance seems less
affected. (Coronary Flow Reserve and Glucometabolic State [CFRGS]; NCT00845468) (J Am Coll Cardiol
Img 2009;2:1159–66) © 2009 by the American College of Cardiology Foundation
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1160here is increasing interest in the associa-
tion between disturbances in glucose metab-
olism and patients with heart disease. Uti-
lizing an oral glucose tolerance test
OGTT), several studies have consistently dem-
nstrated that in addition to the 20% of patients
ith known diabetes mellitus (DM), a further
0% have unrecognized DM, and 30% have
mpaired glucose tolerance (IGT), leaving only
0% with normal glucose metabolism (1). Mor-
ality and morbidity after acute myocardial in-
arction (AMI) are higher among patients with
bnormal glucose metabolism independent of
ther risk factors (2). The increased mortality is
ainly related to a higher incidence of congestive
eart failure, which cannot be explained by a
ore advanced ventricular systolic dysfunction or
an increased risk of adverse remodeling
(3,4). The long-term prognosis of pa-
tients with AMI has improved during
the last 2 decades. However, patients
with overt DM have not achieved the
same improvement in outcome (5). This
together with the increasing incidence
of type 2 DM (6), underlines the impor-
tance of a better understanding of the
pathophysiological factors contributing
to the increased mortality and morbidity
in this large group of patients.
Consequences of abnormal glucose
metabolism are mainly macrovascular
and microvascular disease causing organ
damage. Myocardial microvascular func-
tion can be evaluated by quantification
of the coronary flow reserve (CFR).
CFR reflects the impact on total coro-
nary resistances in terms of epicardial
oronary arteries and the vasodilator capacity of
he microcirculation. A noninvasive and repro-
ucible estimate of CFR may be obtained using
ransthoracic Doppler echocardiography, which
as an excellent correlation with CFR measured
y position emission tomography and magnetic
esonance (7,8) as well as invasive assessment of
FR (9,10). It is, however, uncertain how various
egrees of dysglycemia affect CFR in patients
ith a recent AMI.
Testing the hypothesis that abnormal glucose me-
abolism is a determinant of depressed CFR in pa-
ients with a recent AMI, we studied the relation
etween glucose metabolism and coronary microvas-
ular function, measured by CFR, in the early phase of
ing
ion
ce
y
ionrst AMI. 1E T H O D S
tudy population. Between January 2006 and Au-
ust 2008, 190 patients with first AMI admitted to
he coronary care unit at Funen Hospital, Svend-
org, Denmark, were consecutively screened. Inclu-
ion criteria were as follows: 1) documented AMI
dynamic rise in troponin-T 0.1 g/l, as well as
ither typical symptoms, characteristic electrocar-
iographic changes, or both) regardless of location
f infarction; 2) a patent left anterior descending
rtery (LAD) without any stenosis exceeding 50%
n angiography; 3) an echocardiographic window
llowing the assessment CFR; 4) no contraindica-
ions for coronary angiography; and 5) no history of
ocumented prior AMI, coronary bypass surgery,
alvular heart disease, or poorly controlled obstruc-
ive airway disease. Patients were eligible whether
resenting with ST-segment elevation myocardial
nfarction (STEMI) or with non–ST-segment el-
vation myocardial infarction (NSTEMI). In ad-
ition, patients with anterior AMI were enrolled
f the LAD was patent. Three patients were
xcluded because of significant stenosis in the
AD. Four patients were excluded because of
nability to perform CFR. The final study popu-
ation consisted of 183 patients.
Patients presenting with STEMI within 12 h
f onset of symptoms were transferred to a
ertiary invasive center where acute percutaneous
oronary intervention (PCI) was performed. Ac-
ording to national standard clinical practice,
atients were treated with primary PCI, and for
o patient was thrombolysis used. For patients
resenting with NSTEMI, initial antithrombotic
herapy was instituted and subsequent angiogra-
hy performed within the first week (median 4
ays [3 to 6 days]).The study protocol was
pproved by the Regional Ethics Committee of
outhern Denmark and the Danish Data Protec-
ion Agency, and written informed consent was
btained from all patients.
ssessment of glucometabolic control. Patients with
o history of diabetes had an OGTT performed
efore discharge, in agreement with the European
ociety of Cardiology and European Association for
he Study of Diabetes. After an overnight fast, a 75-g
lucose solution was administered, and capillary whole
lood glucose levels were measured using a HemoCue
01 glucose analyzer (HemoCue AB, A¨ngelholm,
weden). Patients were classified according to theB B R E V I A T I O N S
N D A C R O N YM S
MI acute myocardial
nfarction
FR coronary flow reserve
M diabetes mellitus
GT impaired glucose
olerance
AD left anterior descend
rtery
STEMI non–ST-segment
levation myocardial infarct
GTT oral glucose toleran
est
R odds ratio
CI percutaneous coronar
ntervention
TEMI ST-segment elevat999 World Health Organization (WHO) criteria for
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1161hole blood glucose levels as having newly detected
M if fasting whole blood glucose was 6.1 mmol/l
110 mg/dl) or if the 2-h post-load blood glucose was
11.1 mmol/l (200 mg/dl). IGT was defined as a 2-h
ost-load blood glucose 7.8 mmol/l (140 mg/dl)
nless fasting whole blood glucose met the criteria for
ewly detected DM (11,12).
chocardiography. Transthoracic echocardiography
as performed at a median 5 days [IQR 2 to 9 days]
fter AMI using a commercially available ultrasound
ystem (Vivid 7, GE Medical Systems, Inc., Horten,
orway). All images were analyzed offline by a single
nvestigator, blinded to all clinical data. From standard
hamber projections, left ventricular ejection fraction,
all motion score index, left atrial volume index, early
ransmitral flow velocity to early diastolic mitral an-
ular velocity ratio (E/e= ratio), early transmitral flow
elocity to atrial transmitral flow velocity ratio (E/A
atio), and E-wave deceleration time were obtained
Table 1) (13).
ssessment of CFR. The CFR studies were performed
n an angiographically nonobstructed (50%) LAD.
f a significant LAD stenosis was revealed during
ngiography, CFR was assessed after PCI had been
erformed. If an obstructed (50%) LAD was left
ntreated, the patient was excluded from the study.
mages were obtained in the distal part of the LAD
sing a 7-MHz transducer. The coronary blood flow
as obtained by color Doppler flow-mapping guid-
nce, and a sample volume was positioned within the
olor signal in the LAD artery by the pulse wave
oppler. After baseline recordings of flow velocity,
denosine was administered by intravenous infusion
140g/kg/min) for 90 s, obtaining hyperemic Dopp-
er flow profiles. The CFR was estimated to be the
atio of hyperemic to baseline peak diastolic coronary
ow velocities. A CFR 2 was considered normal
14), and the population was dichotomized according
o this. All subjects abstained from caffeine-containing
rinks for at least 12 h before testing.
All CFR measurements were stored digitally for
uture offline analysis blinded for all clinical variables.
he intraobserver and interobserver variability of cor-
nary flow velocity measurements was 3.6% and 5.3%,
espectively.
aboratory analyses. After an overnight fast, 4 days
range 3 to 8 days) after admission, patients were
tudied by measuring lipid profile and glucose. Crea-
ine kinase-myocardial band and troponin-T levels
ere measured at the time of admission and 6 and
2 h after admission.
tatistical analysis. Analyses and sample size calcula-
ions were conducted with STATA/MP 10.0 (Stata (orp. LP, College Station, Texas). Data are presented
s median (interquartile range [IQR]) and compared
sing Kruskal-Wallis equality-of-populations rank
ests for continuous variables; categorical variables are
resented as counts (percentage) and compared using
hi-square tests. Because significance tests for baseline
haracteristics are presented for descriptive purposes
nly, no adjustment for multiple testing was done.
Univariable logistic regression analysis was used to
valuate the relation between various clinical, echocar-
iographic, and angiographic variables and CFR.
ariables identified in univariable analysis as predic-
ors of an abnormal CFR were subsequently tested in
multivariable model. Data are presented as odds
atios with corresponding 95% confidence intervals. A
alue of p 0.05 was considered statistically significant.
Sample size calculation was based on available
ublications that estimated SD for CFR to be 0.5 in
oth patients with known DM and in healthy con-
rols. To detect a 20% difference between patients
ith DM (known or newly diagnosed), IGT, and
ormal glucose metabolism, respectively, with a power
f 80% and a 2-sided alpha of 0.05, a total sample size
f at least 150 patients was required for the study. We
dentified 109 patients with abnormal CFR, allowing
11 variables to be included in the multivariable
odel.
E S U L T S
linical characteristics. We studied 183 patients (me-
ian age 63 years [IQR 54 to 70 years]; 132 male, 51
emale). OGTT was performed a median of 6 days
IQR 3 to 8 days) after hospital admission. OGTT
uggested normal glucose metabolism in 64 (35%)
atients and abnormal glucose tolerance in 58 (32%)
atients; in 39 (21%) patients, overt DM was diag-
osed, and the remaining 22 (12%) patients had a
istory of DM. Twenty-one of the 39 patients with
ewly diagnosed DM only had post-prandial hyper-
lycemia and no fasting capillary blood glucose capil-
ary value 6.1 mmol/l.
Table 1 shows clinical characteristics and medical
reatment of the patients according to the glucometa-
olic groups. Patients with newly detected and known
M were older and included more males. Statins
ere used more frequently for diabetic patients at
ospitalization, likely explaining the lower total cho-
esterol in this group. The DM group had significantly
igher levels of glycosylated hemoglobin (HbA1c).
We found no differences among the 4 groups
ith respect to Killip classification at admission
p for trend  0.73), or with respect to type
(
l
0
f
c
w
b
o
impaired glucose toleranc n fra
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1162STEMI vs. NSTEMI), enzymatic size, and
ocation of infarction (p values for trend  0.16,
.46, and 0.37, respectively).
For STEMI patients, echocardiography was per-
racteristics According to Glucometabolic Groups
Normal Glucose IGT
64 (35) 58 (32)
59.5 [51.5 to 68] 60.5 [53 to 71]
15/49 12/46
26 [22.6 to 29.1] 27.3 [24.7 to 3
100 [89 to 109] 102 [94 to 107
130 [120 to 150] 137 [123 to 15
80 [70 to 90] 80 [70 to 90]
65 [60 to 75] 65 [60 to 78]
ol/l 4.6 [4.1 to 5.5] 4.6 [3.9 to 5.2
ol/l 2.7 [2.3 to 3.4] 2.7 [2.2 to 3.2
ol/l 1.1 [0.9 to 1.4] 1.0 [0.9 to 1.5
l 1.30 [0.86 to 1.63] 1.26 [0.86 to 1
5.4 [5.1 to 5.7] 5.5 [5.2 to 5.9
5.6 [5.4 to 5.7] 5.6 [5.3 to 5.8
22 (34) 30 (51)
above deﬁnition 44 (69) 48 (83)
mol/l 11 (17) 15 (26)
w deﬁnition 32 (50) 30 (52)
Hg 23 (36) 27 (47)
Hg 10 (16) 11 (19)
17 (27) 24 (41)
0 (0) 0 (0)
syndrome factors, n 2 [1 to 3] 3 [2 to 4]
n
5 (7.8) 6 (10.3)
7 (10.9) 6 (10.3)
0 (0) 0 (0)
9 (14.1) 6 (10.3)
7 (10.9) 8 (13.8)
7 (10.9) 1 (1.7)
9 (14.1) 6 (10.3)
nts 0 (0) 0 (0)
0 (0) 0 (0)
54 [43 to 59] 54.6 [42 to 60]
1.13 [1 to 1.41] 1.06 [1 to 1.44
l/m2 33.7 [26.5 to 39.6] 33.7 [28.2 to 4
9.3 [7.9 to 11.2] 10.3 [8.7 to 12
1.01 [0.84 to 1.4] 1.07 [0.89 to 1
time, ms 181 [157 to 202] 168 [143 to 19
e 2.04 [1.72 to 2.55] 2.02 [1.44 to 2
[interquartile range]. *The p values in this table expressed the trend across groups
rting enzyme; BMI  body mass index; BP  blood pressure; DM  diabetes melli
w velocity to early diastolic mitral annular velocity ratio; fBG  fasting blood gl
e; LA  left atrium; LDL  low-density lipoprotein; LVEF  left ventricular ejectioormed 5 days (IQR 3 to 6 days) after admission, dompared with 7 days (IQR 2 to 11 days) for patients
ith NSTEMI (p 0.02) (Table 2). The time interval
etween the onset of symptoms and the performance
f echocardiography, including measurement of CFR,
New DM Known DM p Value*
39 (21) 22 (12)
67 [60 to 73] 63 [57 to 75] 0.005
19/20 5/17 0.01
26.8 [23.7 to 29.9] 28.6 [23.2 to 33.3] 0.1
102 [93 to 111] 106.3 [95 to 122.5] 0.09
150 [130 to 164] 140 [115 to 156] 0.2
80 [70 to 92] 70 [74 to 90] 0.9
68 [61 to 84] 74 [60 to 100] 0.06
4.3 [3.7 to 5] 3.8 [3.3 to 4.1] 0.004
2.6 [1.9 to 3.1] 2.1 [1.8 to 2.4] 0.003
1.0 [0.9 to 1.2] 1.1 [0.8 to 1.3] 0.4
1.35 [1.05 to 1.75] 1.31 [1.14 to 1.57] 0.9
6.4 [5.8 to 6.8] 7.7 [5.5 to 9.7] 0.0001
5.9 [5.6 to 6.3] 7.0 [6.5 to 7.9] 0.0001
28 (71) 15 (68) 0.005
35 (90) 19 (86)
10 (26) 4 (18)
25 (64) 13 (59)
24 (62) 9 (41)
9 (23) 4 (18)
32 (82) 16 (73)
0 (0) 22 (100)
4 [3 to 5] 5 [5 to 6]
6 (15.4) 7 (31.8) 0.01
7 (17.9) 4 (18.2) 0.15
0 (0) 1 (4.5) 0.02
3 (7.7) 9 (40.9) 0.001
4 (10.3) 6 (27.3) 0.064
6 (15.4) 4 (18.2) 0.02
9 (23.1) 9 (40.9) 0.004
0 (0) 12 (54.5) 0.0001
0 (0) 7 (31.8) 0.0001
51 [43 to 58] 49.9 [42 to 57] 0.8
1.25 [1 to 1.63] 1.41 [1.14 to 1.56] 0.13
32.6 [24.4 to 36.8] 35.7 [29.1 to 44.4] 0.31
11.4 [10.5 to 13.8] 10.9 [8.2 to 17.1] 0.0013
0.95 [0.75 to 1.08] 1.125 [0.75 to 1.29] 0.14
185 [167 to 227] 198 [147 to 247] 0.14
1.63 [1.3 to 2] 1.42 [1.13 to 1.67] 0.0001
tabolic syndrome is deﬁned according to the International Diabetes Federation.
/A ratio  early transmitral ﬂow velocity to atrial transmitral ﬂow velocity ratio;
e; HbA1c  glycosylated hemoglobin; HDL  high-density lipoprotein; IGT 
ction; WMSI  wall motion score index.Table 1. Baseline Cha
Patients
Age, yrs
Sex, female/male
BMI, kg/m2 0.3]
Waist measurement, cm ]
Systolic BP, mm Hg 0]
Diastolic BP, mm Hg
Heart rate, beats/min
Biochemistry
Total cholesterol, mm ]
LDL cholesterol, mm ]
HDL cholesterol, mm ]
Triglycerides, mmol/ .71]
fBG plasma, mmol/l ]
HbA1c, % ]
Metabolic syndrome†
Metabolic syndrome
Waist measurement
Triglycerides 1.7 m
HDL cholesterol belo
Systolic BP 130 mm
Diastolic BP 85 mm
fBG plasma, mmol/l
Prior diagnosis of DM
Median of metabolic
Treatment at admissio
Acetylsalicylic acid
Beta-blockers
Clopidogrel
Statins
ACE inhibitors
Ca2-blockers
Diuretics
Oral antidiabetic age
Insulin therapy
Echocardiography
LVEF, %
WMSI ]
LA index volume, m 0.6]
E/e= .3]
E/A ratio .31]
E-wave deceleration 7]
Coronary ﬂow reserv .65]
Values are n (%) or median . †Me
ACE  angiotensin-conve tus; E
E/e=  early transmitral ﬂo ucosid not differ among the study groups. We
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1163ound no differences in echocardiographic parameters
etween the glucometabolic groups concerning left
entricular ejection fraction, wall motion score index,
eft atrial volume, E/A ratio, and mitral wave decel-
ration time (p values for trend 0.8, 0.13, 0.31, 0.14,
nd 0.14, respectively). We found a trend toward an
ncreased E/e= according to worsening glucometabolic
tate (p for trend  0.0013) (Table 1).
oronary ﬂow reserve. Median CFR was 1.9 (IQR
.4 to 2.4). In 109 (60%) patients, a CFR 2 was
ound. The lowest CFR, 1.4 (IQR 1.4 to 1.7), was
etected in patients with a known history of DM.
FR was also reduced in patients with newly diag-
osed DM (1.6 [IQR 1.3 to 2], p  0.09) versus a
nown history of DM, but no difference was observed
n patients with abnormal glucose tolerance (2.1 [IQR
.4 to 2.6]) and normal glucose tolerance (2.2 (IQR
.7 to 2.6 ]) (Fig. 1).
Patients with a decreased CFR (2) were older
nd had a significantly lower heart rate and higher
iastolic blood pressure than did patients with
ormal CFR (Table 3). In patients revascularized in
he LAD, CFR was 1.9 (IQR 1.3 to 2.3) compared
ith patients not revascularized in the LAD (1.9
IQR 1.5 to 2.6], p  0.11). There was no
ifference in CFR between STEMI patients (1.91
IQR 1.5 to 2.4]) and NSTEMI patients (1.96
IQR 1.4 to 2.4], p  0.38) (Table 2).
Performing a chi-square analysis across all subsets
f glucometabolic groups, we found a significant
ncrease in patients with CFR 2 (p  0.0001).
Furthermore, in a stepwise logistic regression
odel adjusting for age, sex, site of AMI, size of
MI (peak creatine kinase-myocardial band), heart
ate, risk factors for the metabolic syndrome, degree
f angiographic evidence of coronary artery disease,
nd relevant medical therapy, newly diagnosed DM
odds ratio: 3.0 [95% confidence interval: 1.1 to
.7], p  0.049) and a known history of DM (odds
atio: 9.9 [95% confidence interval: 1.5 to 73.3],
 0.03) remained significant predictors of CFR
2, whereas impaired glucose tolerance was not
Fig. 2).
ngiographic and angioplasty data. Angiographic
ata are presented in Table 4. In 127 patients,
uccessful PCI was performed. Thirty-three pa-
ients did not undergo PCI, and among those, 10
nderwent subsequent coronary artery bypass sur-
ery. In 23 patients, angiography did not reveal
ignificant stenoses (50%). In 74 patients, PCI
as performed in the LAD; 69 patients achieved
hrombolysis In Myocardial Infarction (TIMI)
ow grade 3 in the LAD, and 5 achieved TIMIow grade 0 to 2. Drug-eluting stents were im-
lanted in 140 patients, and 63 patients received
ptifibatid/abciximab infusion during and after the
CI procedure. No differences in the number of
iseased vessels and TIMI flow grade before and after
ntervention were seen in patient groups (Table 4).
I S C U S S I O N
lthough substantial evidence supports the premise
hat hyperglycemia affects the coronary microcircu-
ation, this is the first study to assess the impact of
nown DM, newly diagnosed DM, and IGT on
FR in a consecutive population with a recent
MI. We demonstrate that noninvasive assessment
Figure 1. CFR According to Glucometabolic Status
Box plot of the mean values of coronary ﬂow reserve (CFR) accordi
status. The mean value of CFR is gradually decreased according to
metabolic state and illustrates the degree of disturbed microvascula
Table 2. Baseline Characteristics According to STEMI Versus NS
STEMI N
Patients 94 (51)
Sex, female/male 20/74
CFR 1.91 [1.5 to 2.4] 1.96 [
WMSI 1.19 [1 to 1.63] 1.14 [
LVEF, % 53.5 [41 to 60] 53.8 [
Time from admission to revascularization, h 1.5 [0.5 to 2.5] 102 [
Time from admission to estimation of CFR,
days
5 [3 to 6] 7 [
Culprit lesion
Left anterior descending artery 45 (48)
Right coronary artery 35 (37)
Left circumﬂex artery 14 (15)
Values are n (%) or median [interquartile range].
CFR  coronary ﬂow reserve; NSTEMI  non–ST-segment elevation myoca
ST-segment elevation myocardial infarction; other abbreviations as in Table 1.ng to glucometabolic
worsening gluco-
r function in dysgly-TEMI
STEMI p Value
89 (49) 0.8
31/58 0.11
1.4 to 2.4] 0.38
1 to 1.44] 0.3
44 to 58] 0.2
75 to 137.5] 0.0001
2 to 11] 0.02
40 (45) 0.7
30 (34) 0.7
19 (21) 0.3
rdial infarction; STEMI cemic patients. DM  diabetes mellitus; IGT  impaired glucose tolerance.
o
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1164f CFR is feasible for a large consecutive population
ith AMI. In addition, the study demonstrates a
ersistent association between depressed CFR and
vert or newly diagnosed DM after adjustment of
Figure 2. Odds Ratios for CFR <2 According to Glucometabolic
Unadjusted and adjusted (not illustrated) odds ratios (OR) for coron
illustrates the exponential increase for CFR 2 in OR according to g
adjusted for age, sex, location of infarction, type of infarction, infarc
metabolic syndrome risk factors, degree of angiographic coronary a
racteristics According to CFR
CFR <2 CFR >2 p Value
109 (59.6) 74 (40.4)
64 [57 to 73] 58 [51 to 68] 0.003
34/75 17/57 0.2
140 [120 to 160] 135 [120 to 150] 0.75
80 [70 to 90] 80 [72 to 90] 0.59
66 [60 to 75] 61 [54 to 68] 0.002
55 (50.5) 43 (58.1) 0.3
22 (20.2) 6 (8.1) 0.8
5.7 [5.3 to 6.5] 5.6 [5.2 to 6.1] 0.3
5.8 [5.5 to 6.3] 5.6 [5.4 to 5.9] 0.01
-MB, g/l 59.1 [20.8 to 174.5] 49.1 [19.6 to 144] 0.3
1.02 [0.41 to 4.95] 0.94 [0.33 to 2.47] 0.1
est,
5.2 [4.6 to 5.7] 5.1 [4.6 to 5.6] 0.6
9.2  3.0 7.9 [6.6 to 8.8] 0.0007
52 [41 to 56] 56 [45 to 60] 0.02
n [interquartile range].
ther abbreviations as in Tables 1 and 2.OR is not illustrated. Abbreviations as in Figure 1.ossible confounders. However, we were unable to
emonstrate a similar association in patients with
GT in whom CFR was no different from CFR in
atients with normal glucose metabolism.
Hyperglycemia has been shown to suppress cor-
nary microcirculation in healthy young adults (15).
everal mechanisms may explain the association
etween hyperglycemia and microvascular dys-
unction. Persistent hyperglycemia may cause
icrovascular dysfunction through leukocyte
apillary plugging, enhanced platelet activation,
nd accumulation of advanced glycation products
16,17).
A puzzling finding was that CFR was not de-
ressed in patients with IGT compared with pa-
ients with normal glucose metabolism. Other
roups have observed abnormal microvascular func-
ion in patients with IGT (18), although the diag-
osis was made on the basis of admission glucose
evels rather than on an OGTT. In our study, the
ack of association may be a result of heterogeneity.
hese patients may represent a mixture of persons
ith larger infarcts, with resulting stress hypergly-
emia, as well as patients with pre-existing IGT
19). We found no difference in HbA1c, and this
ould confirm that longstanding hyperglycemia was
ot present in the majority of patients with IGT.
bA1c may be normal despite post-prandial hy-
tus
ﬂow reserve (CFR) 2 according to metabolic groups. The ﬁgure
metabolic state. *The adjusted OR is not illustrated. The OR is
e (peak creatine kinase-myocardial band [mikrg/l]), heart rate,
y disease, and relevant drug therapy. **The age- and sex-adjustedSta
ary
luco
t siz
rterTable 3. Baseline Cha
Patients
Age, yrs
Sex, female/male
Systolic BP, mm Hg
Diastolic BP, mm Hg
Heart rate, beats/min
Current smoker
Killip class II
Biochemistry
fBG plasma, mmol/l
HbA1c, %
Peak creatine kinase
Troponin-T
Oral glucose tolerance t
mmol/l
fBG capillary
2-h capillary glucose
Echocardiography
LVEF, %
Values are n (%) or media
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1165erglycemia, which may play a significant role in
he development of both microvascular and macro-
ascular complications (20).
In hearts with acute infarct, basal and hyper-
mic blood flow may be reduced not only in the
nfracted area but also in remote segments of
he myocardium. We also found reduced CFR in
he LAD territory in many patients whose LAD
as not the culprit, and that may be representa-
ive of decreased microvascular function in the
ntire heart. The underlying mechanisms may
nclude compromised microcirculation due to
yocardial stunning in the infarct zone and
ntramyocardial edema causing partial oblitera-
ion of the microvasculature and a disturbed
erfusion of the non-necrotic tissue (21).
In the present study, OGTT suggested normal
lucose tolerance in only one-third of the pa-
ients. This finding corresponds well with other
bservational studies (22). Our results indicating
icrovascular disease in patients with DM is in
greement with previous studies of DM patients
ithout overt ischemic heart disease (23) in
hich CFR was demonstrated to be impaired
ven in the absence of significant epicardial
oronary atherosclerosis (24).
To further characterize and to assess whether the
icrovascular abnormalities in dysglycemic patients
ith a recent MI represent reversible or irreversible
hanges in the microvascular function, future stud-
es should include serial measurements to assess
emporal changes in microcirculation and further-
ore assess myocardial viability.
tudy limitations. Timing of echocardiography was
ifferent in patients with STEMI and NSTEMI.
he measurements of CFR were performed with a
elay in the NSTEMI group who underwent an-
iography after initial stabilization, compared with
he STEMI group who underwent urgent PCI.
urthermore, the rather large time span was caused
y the local logistical arrangement, as described in
he Methods section. Although we found no clear
ssociation between the timing of CFR and the
iming of revascularization, we cannot exclude a
ias due to timing of the investigations.
We observed a larger number of patients with
-vessel disease in the group with diminished mi-
rovascular circulation, although not present at the
ime of CFR measurement. Our finding may reflect
ncreased microvascular dysfunction with increased
acrovascular disease. Furthermore, we note the
elative low median CFR that may be a result of the bonfounding mechanism caused by microvessel im-
airment in post-AMI patients.
Although assessment of CFR has been validated
gainst invasive measures of CFR, the accuracy is
nfluenced by the image quality and angle depen-
ence of Doppler velocities that may limit the
xactness in the individual patient.
Finally, it is mandatory to take the heart rate into
ccount during measurement of CFR. An increased
eart rate demands more oxygen to the myocar-
ium. By autoregulatory mechanisms, the recruit-
ent of the microvasculature increases, resulting in
ecreased CFR (25).
linical implications. The present study suggests that
FR is reduced in patients with known or newly
iagnosed DM, even after adjustment for possible
onfounders. Given the difficulties in risk-
tratifying diabetic patients, considering that con-
entional stress testing by wall-motion analyses
nadequately identifies high-risk patients (26,27),
FR may prove to be a valuable tool to assess risk
or this subset of patients.
eprint requests and correspondence: Dr. Brian B. Løg-
trup, Department of Medical Research, Funen Hospital
vendborg, 5700 Svendborg, Denmark. E-mail:
Table 4. Angiographic Characteristics
CFR <2
(n  109)
C
(n
No signiﬁcant vessel disease, n (%) 7 (6.4) 8
1 vessel disease, n (%) 65 (59.6) 48
2 vessel disease, n (%) 28 (25.7) 14
3 vessel disease, n (%) 9 (8.3) 4
Left main stem included, n (%) 7 (6.4) 3
Culprit lesion, n (%)
Left anterior descending 45 (41.3) 29
Right coronary artery 46 (42.2) 37
Left circumﬂex 18 (16.5) 18
Coronary angiography before intervention
TIMI ﬂow grade, n (%)
0 44 (40.4) 30
1/2 4/17 (3.6/15.6) 5/9
3 44 (40.4) 30
Coronary angiography after intervention
TIMI ﬂow grade, n (%)
0 3 (2.75) 0
1/2 0/3 (0/2.75) 2/3
3 103 (94.5) 69
CFR  coronary ﬂow reserve; TIMI  Thrombolysis In Myocardial Infarction.FR >2
 74) p Value
(10.8) 0.06
(64.9) 0.5
(18.9) 0.3
(5.4) 0.5
(4.1) 0.2
(39.2) 0.8
(36.5) 0.5
(24.3) 0.1
(40.5) 0.9
(6.7/12.3) 0.3/0.5
(40.5) 0.9
(0) 0.2
(2.7/4.1) 0.08/0.6
(92.2) 0.5bl@dadlnet.dk.
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